Pandas

3

Review clinical trials related to Pandas. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study

The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regard to spectrum, course and outcome. The investigators aim to demonstrate they can recruit and retain 85% of children who are eligible for this study. Eligible children are those who fit criteria for PANS and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS). Each child will be followed for one year.

Participants needed: 30
Trial details
Age: 3-17Biological sex: AllType: ObservationalSponsor: University of Wisconsin, MadisonUpdated: Jan 27, 2026Locations: 2
Eligibility criteria

Child age 3-17 years old [+19]

History of tics, OCD or food restriction/avoidance that contradicts a history of... [+4]

Status: Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. "Healthy" individuals without brain inflammation are also eligible to participate. The digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.

Participants needed: 10,000
Trial details
Age: 2+Biological sex: AllType: ObservationalSponsor: Brain Inflammation CollaborativeUpdated: Jan 22, 2026Locations: 1Duration: 10 Years
Eligibility criteria

Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgi... [+8]

Status: Recruiting

Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS

This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (OCD) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral (developmental) regression, sensory amplification, movement abnormalities, sleep disturbance, and urinary frequency. PANS is thought to be caused by infection, inflammation, or alternate triggers that is associated with a brain response that leads to these symptoms. The purpose of this study is to examine specific neurologic, immunologic, rheumatologic, and genomic, components in children with the acute-onset of psychiatric symptoms. This research may begin to uncover a much larger story of autoimmune processes that are involved in psychiatric disorders of childhood. By better understanding the etiologic components of psychiatric phenomenon, future treatments may be better targeted to underlying causes.

Participants needed: 500
Trial details
Age: 4-18Biological sex: AllType: ObservationalSponsor: Stanford UniversityUpdated: Oct 6, 2016Locations: 1
Eligibility criteria

Children with PANS [+7]

Any neuropsychiatric illness that may obscure the clear diagnosis of PANS